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Abstract Zinc (Zn) deﬁciency is a problem world-
wide. Current methods for assessing Zn status are
limited to measuring plasma or serum Zn within
populations suspected of deﬁciency. Despite the high
prevalence of Zn deﬁciency in the human popula-
tion there are no methods currently available for
sensitivelyassessingZn status amongindividuals. The
purpose of this research was to utilize a proteomic
approach using two-dimensional gel electrophoresis
(2DE) and mass spectrometry to identify protein
biomarkers that were sensitive to changes in dietary
Zn levels in humans. Proteomic analysis was per-
formed in human plasma samples (n = 6) obtained
from healthy adult male subjects that completed a
dietary Zn depletion/repletion protocol, current die-
tary zinc intake has a greater effect on fractional zinc
absorption than does longer term zinc consumption in
healthy adult men. Chung et al. (Am J Clin Nutr 87
(5):1224–1229, 2008). After a 13 day Zn acclimati-
zation period where subjects consumed a Zn-adequate
diet, the male subjects consumed a marginal Zn-
depleted diet for 42 days followed by consumption of
a Zn-repleted diet for 28 days. The samples at
baseline, end of depletion and end of repletion were
pre-fractionated through immuno-afﬁnity columns to
remove 14 highly abundant proteins, and each fraction
separated by 2DE. Following staining by colloidal
Coomassie blue and densitometric analysis, three
proteins were identiﬁed by mass spectrometry as
affected by changes in dietary Zn. Fibrin b and chain
E, fragment double D were observed in the plasma
protein fraction that remained bound to the immuno-
afﬁnity column. An unnamed protein that was related
to immunoglobulins was observed in the immunode-
pleted plasma fraction. Fibrin b increased two-fold
following the Zn depletion period and decreased to
baseline values following the Zn repletion period; this
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Introduction
Zinc(Zn)isanessentialtraceelementnecessaryforthe
normal growth and development of all organisms. The
average adult human body contains 2.3 g of Zn, an
amountsecond onlytoiron(Coleman 1992).Over300
enzymes require Zn as a structural component or
within the active site (Coleman 1992). Zn ﬁnger
transcription factors (Cys2 His2) are encoded by
approximately 3 % of the human genome, comprising
709 genes. Another 48 genes encode the thyroid and
steroid hormonenuclear receptorgenefamilies(Cys4)
(Klug 2010). Other Zn-binding motifs that have been
identiﬁed include Cys3HisCys4 (RING ﬁnger) and
Cys2HisCys5 (LIM domain) (Berg and Shi 1996). Zn
is necessary for insulin metabolism (Emdin et al.
1980), and for insulin signaling (Jansen et al. 2009).
Consequently, Zn plays a role in numerous biochem-
ical and physiological pathways, including those
involved in gene expression, signal transduction, and
antioxidant protection (Song et al. 2009; Sakaguchi
etal.2002;TaylorandBray1991;Sullivanetal.1980).
Inadequate consumption of Zn is a worldwide
problem. There is a medium to high risk of Zn
deﬁciency worldwide (International Zinc Nutrition
Consultative Group 2004), with a signiﬁcant number
of Americans consuming less than the estimated
average requirement for Zn. For children less than
5 years of age Zn deﬁciency is estimated to
cause *8,00,000 deaths from malaria, diarrhea, and
pneumonia, with a loss of disability-adjusted life years
of 28 million (Cauﬁeld and Black 2004).
Determining the degree of marginal zinc deﬁciency
within different human populations, as well as the
ability to diagnose marginal zinc status among indi-
viduals, is the goal. The current list of potential
biomarkers lacks the sensitivity and speciﬁcity for
individual assessment, making it difﬁcult to interpret
the relevance of reports of inadequate Zn intake in
otherwise healthy individuals including infants and
children (Hambidge 2000). Studies to investigate the
responses of Zn transporter proteins have been
reported. In mouse erythrocyte plasma membrane,
SLC30A1 (ZnT1) and SLC39A10 (Zip10), responded
to dietary Zn deﬁciency (Ryu et al. 2008). Humans
consuming a severely Zn deﬁcient diet for 10 days
exhibited signiﬁcant reductions in peripheral blood
mononuclear cell metallothionein mRNA, and mRNA
from members of the SLC30A Zn transporter family
(ZnT1, ZnT4, ZnT5). Reticulocyte ZnT1 and Zip3
mRNA similarly responded to dietary Zn deﬁciency.
In addition, at least 20 serum microRNA species were
responsive to dietary Zn depletion for 10 days
followed by repletion for 7 days (Ryu et al. 2011).
The objective of this study was to measure plasma
proteins from individuals consuming a marginal Zn-
depleted diet for 42 days followed by consumption of
a Zn-repleted diet for 28 days. This protocol could be
considered closer to what is experienced in the general
population, the consumption of a marginally deﬁcient
diet for weeks to months. We hypothesize that speciﬁc
circulating plasma proteins will exhibit measurable
responses to changes in dietary zinc. The identiﬁed
proteins may ultimately serve as biomarkers for
marginal zinc status in humans upon validation in
the future using signiﬁcantly more subjects.
Experimental
The plasma samples used in this study were from a
previous Zn depletion/repletion study performed in
healthy male volunteers. Details of subject recruit-
ment, inclusion/exclusion criteria and subject charac-
teristics can be found in Chung et al. (2008) and Song
et al. (2009). The dietary protocol from Chung et al.
(2008) is shown in Fig. 1. Brieﬂy, during the accli-
matization period, (days 1–13), an adequate zinc diet
(11 mg Zn/day) was given for 13 days to ensure
adequate zinc status. During the Zn depletion period,
(days 14–55), the subjects were given a liquid diet
containing 0.6 mg Zn/day for 7 days followed by a
low zinc diet (4 mg Zn/day) for another 35 days.
Finally, during the Zn repletion period, (days 56–83),
the subjects consumed a zinc adequate (11 mg Zn/
day) diet for 28 days, with supplemental zinc (20 mg/
d zinc as zinc gluconate) administered for the ﬁrst
7 days. The subjects consumed a daily multiple
vitamin supplements (100 % RDA) without minerals
(Long’s Pharmacy, CA) throughout the study. Plasma
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123from three time points was analyzed in the current
study, day 13 (end of acclimation), day 55 (end of
depletion), and day 83 (end of repletion). Plasma from
6 individuals from the previous study was pre-
fractionated, and analyzed by two-dimensional gel
electrophoresis (2DE) and mass spectrometry for the
current study.
Fourteen high-abundance proteins were removed
using the Seppro
 IgY 14 immunoafﬁnity spin
columns (Sigma). The columns contain antibodies
against the following human proteins: albumin, a1-
antitrypsin, a1-acid glycoprotein, a2-macroglobulin,
apolipoproteins A-I and A-II, apolipoprotein B, com-
plement C3, ﬁbrinogen, haptoglobin, IgA, IgG, IgM,
and transferrin (Bjorhall et al. 2005). Before pre-
fractionating each sample, storage buffer (25 mM
Tris, 25 mM NaCl, 0.01 % sodium azide; pH 7.5) was
removed through centrifugation, and the columns
were washed twice using 19 dilution buffer (100 mM
Tris-Buffered Saline, 1 M Tris–HCl with 1.5 M NaCl,
pH 7.4). After each wash, columns were centrifuged
(30 s; 2,0009g). Each sample was prepared in dupli-
cate, and both fractions were pre-fractionated simul-
taneously. A sample volume of 20 ll was combined
with 480 llo f1 9 dilution buffer for a total volume of
500 ll sample fraction dilution, the minimum volume
recommended for loading columns. Each fraction was
transferred to a 0.45 lm spin ﬁlter (one per sample)
and centrifuged (1 min; 10,0009g) to remove partic-
ulates, such as lipids, that could impede analysis. This
step was staggered with washing of the columns so
that upon ﬁnal centrifugation of the columns; the
ﬁltered samples could be added to the columns
immediately, preventing any damage to the beads
from excessive drying. Samples were then added to
columns and processed according to kit instructions.
Both the immunodepleted plasma and the bound
protein fractions were saved for analysis. The protein
concentration of the both fractions was measured
using a modiﬁed Lowry method (Lowry et al. 1951).
The bound (highly abundant) and immunodepleted
(low/medium abundant) plasma protein fractions were
separated in triplicate. 75 lg protein was taken from
each fraction in order to load 225 lg protein on to
immobilized pH gradient (IPG) strips. The protein in
each sample was concentrated by acetone precipita-
tion. Four volumes of acetone were added to each
sample,andsampleswerefrozenat-80 Cforatleast
30 min. Following centrifugation (20 min; 10,0009g)
the pellet was resolubilized in 125 ll protein solubi-
lization buffer (Bio-Rad proprietary composition).
The following was added to the samples containing
protein solubilization buffer: 2 mM tributyl phos-
phine, 0.2 %ampholyte, 0.0002 %bromophenolblue.
Samples were then pipetted into a clean isoelectric
focusing (IEF) tray, and 3–10 IPG strips (Bio-Rad
ReadyStrips
TM, 7 cm,) were laid on top. Mineral oil
was applied atop the strips, 1.5 ml per lane. The
solubilized sample mixture was adsorbed to the strips
via active rehydration for approximately 15.5 h in a
Bio-Rad Protean IEF cell set at 20 C. IEF ran
approximately 7.5 h on a rapid preset method with
Fig. 1 Zn depletion and
repletion protocol. Subjects
consumed 11 mg Zn/d for
13 days during the baseline
period. The depletion period
began with the consumption
of 0.6 mg Zn/d for 8 days
followed by 4 mg Zn/d for
34 days. The repletion
period extended for 28 days
startingwithconsumption of
20 mg Zn/d for 8 days, then
11 mg Zn/d for 20 days.
(adapted from Chung et al.
2008)
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123the following settings: 20,000 VH, 4,000 V/20 C,
and 50 lA current per strip. Strips were drained onto a
clean paper towel and placed in lanes of a clean IEF
storage tray. The tray was wrapped in Saran wrap and
stored at -80 C until ready to perform the second
dimension.
IPG strips containing the proteins were thawed
exactly 15 min at room temperature and equilibrated
with second dimension equilibration buffer (6 M urea,
0.375 M Tris, 2 % sodium dodecyl sulfate, 20 %
glycerol, 2 mM tributyl phosphine) for 20 min with
gentle agitation. Strips were placed into wells and
positioned ﬂush against the polyacrylamide gel. The
denaturing slab gels were composed of 15 % acrylam-
ide and the second dimension was run using Tris–
Glycine–sodiumdodecyl sulfate buffer, with a constant
current of 30 lA per gel. Gels were ﬁxed with a 40 %
methanol/10 % acetic acid solution for at least 30 min.
After removing the ﬁxative, gels were washed with
ddH2O( 39 10 min). Proteins were stained with col-
loidal Coomassie G-250 blue-silver stain (10 % phos-
phoric acid 10 % ammonium sulfate, 20 % methanol,
0.12 %CoomassieG-250)foraminimumof6.5 hwith
gentle agitation (Candiano et al. 2004). The gels were
destained with ddH2O until the background was clear.
The gels were digitally scanned using HP Preci-
sionScan Pro 3.1 software. The spot densities were
measured, and differences determined, using Phoretix
2D Analysis software (V6.01c). The data were
normalized by subtracting the background intensity
from the total intensity of each spot. Spots showing
signiﬁcant variance were selected and manually
excised from the gels. Excised spots were sent to the
Proteomics Core Laboratory at the Georgia Health
Sciences University for in-gel tryptic digestion, mass
spectrometry analysis and protein identiﬁcation using
GPS Explorer to compare the spectra to sequence
information found in the standardized databases
Protein Prospector, ProFound, and Mascot. For each
spot, the protein with the highest conﬁdence interval
of the ten possibilities, the closest matching in silico
molecular weight and pI to the experimentally deter-
mined molecular weight estimated with the gel
standards, was selected as the protein identity.
2DE was performed in triplicate for the plasma
samples from each individual, and for each plasma
protein fraction. The technical replicates from indi-
vidual protein spots were averaged for each individual
at each time point. The data from each protein spot is
based on the biological replicate of six individuals at
each time point. ANOVA was used to identify
signiﬁcant differences based on dietary treatment
(p B 0.05). Post-hoc analysis to identify signiﬁcant
differences was determined by Fishers Least Signif-
icant Differences.
Results and discussion
The subject characteristics from the original study and
a follow-up study have been reported previously
(Chung et al. 2008; Song et al. 2009). A summary of
the subject characteristics, and the results from their
plasma Znanalysis,follows.Atthe startofthe original
study (Chung et al. 2008), the age of the subjects was
38 ± 8 (SD) y. Their body mass index was between
20.8 and 25.9 kg/m
2. None of the subjects were
anemic. Their dietary zinc intake at the beginning of
the study was 12.9 ± 2.2 (SD) mg/d and their plasma
zinc concentrations averaged 84.8 ± 8.5 (SD) lg/dL.
Plasma Zn levels were measured at the end of the
acclimatization period (day 13), the Zn depletion
period (day 55) and the Zn repletion period (day 83).
No change was observed between day 13 and day 55
(79 ± 9 (SD) lg/dL and 79 ± 10 (SD) lg/dL,
respectively). However, there was a signiﬁcant 13 %
increase in plasma Zn measured on day 83 (86 ± 10
(SD) lg/dL; p = 0.02) compared to day 55 (Chung
et al. 2008; Song et al. 2009).
In the current study, the plasma from baseline, Zn-
depleted and Zn-repleted subjects was fractionated by
immunoafﬁnity columns to remove 14 highly abun-
dant proteins, resulting in bound and immunodepleted
protein fractions. The proteins in these fractions were
separated by 2DE. Figure 2 shows the electrophoretic
pattern obtained from those proteins bound by the
immunoafﬁnity column (Bound) and the immunode-
pleted plasma containing those proteins remaining in
the efﬂuent (Immunodepleted). The protein spots
whose levels were signiﬁcantly affected by dietary
zinc are labelled by their accession number.
The identity of the protein spots was determined by
MALDI-TOF mass spectrometry (Table 1). Two
proteins, ﬁbrin b (accession number gi|223002) and
chain E, fragment double D from human ﬁbrin
(accession number gi|28373962), in the bound plasma
protein fraction are byproducts of hemostasis; one
protein, (accession number gi|34527413), in the
136 Biometals (2013) 26:133–140
123immunodepleted fraction remains unnamed, though it
is related to immunoglobulins. Each of the proteins
identiﬁed by mass spectrometry exhibited an ion
conﬁdence interval (CI) of[99 %.
The data indicate that hemostasis is affected by
consumption of a Zn depleted diet. Figure 3 shows the
responses that these three plasma proteins exhibited to
changes in dietary Zn. Fibrin b increased approxi-
mately 2-fold by the end of the depletion period
compared to baseline and decreased back to baseline
levels by the end of the repletion period. No such
change in plasma Zn levels was observed in the
original study (Chung et al. 2008). This protein is a
product of the coagulation cascade, catalysed by
thrombin which cleaves ﬁbrinopeptides a and b from
ﬁbrinogen resulting in clot formation (Nesheim 2003).
Zn has been shown to reduce clotting times in a
concentration-dependent manner by accelerating
ﬁbrin assembly (Marx and Eldor 1985; Marx and
Hopmeier 1986; Marx et al. 1987). Dietary Zn
deﬁciency is known to impair platelet aggregation
and hemostasis (Tubek et al. 2008). Zn has been
shown to inhibit the release of ﬁbrinopeptide a during
thrombin-inducedclotformation(MarxandHopmeier
1986). Conversely, one might expect that Zn deﬁ-
ciency may increase the release of ﬁbrinopeptide a.
Though an increase in ﬁbrinopeptide a was not
observed in the current proteomic analysis, the release
of ﬁbrinopeptide b occurs sequential to the release of
ﬁbrinopeptide a (Nesheim 2003); the resulting ﬁbrin b
may be biomarker for dietary Zn deﬁciency. However,
the ﬁndings of the current study need to be validated
using a much larger sample size.
Liver damage also affects liver ﬁbrin levels in a rat
model for cirrhosis induced by thio acetamide (Dashti
et al. 1997). Zn supplementation was effective for
reversing the liver damage. Cirrhotic changes in the
liver increased liver ﬁbrin, while Zn decreased ﬁbrin
Fig. 2 Representative 2DE
gels showing the molecular
wt. standards on the left side
of each gel image, and the
acidic and basic ends.
Plasma was pre-fractionated
prior to separation by 2DE;
representative 2DE gels are
shown from the BOUND
(immunoafﬁnity bound) and
IMMUNODEPLETED
plasma proteins. The protein
spot IDs are shown as
accession numbers
Table 1 Identities of plasma protein spots exhibiting signiﬁ-
cant differences between treatments. Tryptic peptides from
each protein spot were identiﬁed by mass spectrometry. The
protein conﬁdence intervals exceeded 94 % and the ion
conﬁdence intervals exceeded 99 %
Protein score Protein CI % Protein name Peptide
count
Total ion
score
Ion
CI %
Accession
number
244 100 Fibrin b 14 208 100 gi|223002
83 99.929 Chain E, fragment double-D
from human ﬁbrin
6 75 100 gi|28373962
64 94.461 Unnamed protein 11 44 99.68 gi|34527413
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123in the liver (Dashti et al. 1997). The observed increase
in plasma ﬁbrin b in response to dietary Zn deﬁciency
from this study may be related to increases in liver
ﬁbrin induced by Zn deﬁciency. Zn deﬁciency is pro-
inﬂammatory through stimulation of NFjB DNA
binding and inhibition of PPARa transactivation
activity, which are also linked to coagulation and
ﬁbrinolysis pathways (Shen etal. 2008). The protein C
pathway is another link between inﬂammation and
hemostasis where Zn status may be an important
component (Esmon 2003; Sen et al. 2010). Zn also
stimulates the intrinsic (Shore et al. 1987; Bernardo
et al. 1993), and inhibits the extrinsic (Pedersen et al.
1991, 2000), pathways of coagulation.
Another possible linkbetweenZnand ﬁbrin may be
through the protein decorin (Tubek et al. 2008). The
amino terminus of decorin binds to the ﬁbrinogen D
fragment in a Zn-dependent manner, and modulates
ﬁbrin assembly (Dugan et al. 2003, 2006). Fibrinogen-
bound decorin is more susceptible to proteolysis by
tissue-plasminogen activator; physiological concen-
trations of Zn decrease this interaction (Dugan et al.
2006). The observed increase and decrease in ﬁbrin b
with Zn depletion/repletion may be due to Zn-
dependent changes in decorin binding to ﬁbrinogen
during normal hemostasis.
There was no signiﬁcant change between baseline
and the end of the depletion period in chain E,
fragment double D from ﬁbrin. The levels of this
protein signiﬁcantly increased more than 2-fold by the
end of the repletion period. These fragments are
generated during ﬁbrinolysis, and are ﬁbrin degrada-
tion products from the cleavage by plasmin of the a, b,
and c chains of ﬁbrin at speciﬁc arginine and lysine
residues (Nesheim 2003). The response of the chain E,
fragment double D to dietary Zn may be the result of
changes in the activity of thrombin-activatable ﬁbri-
nolysis inhibitor. This metalloproteinase has 40 %
amino acid homology to pancreatic carboxypeptidase
B, and is inactivated by the Zn chelator o-phenan-
throline (Eaton et al. 1991; Marx et al. 2002). The
holo-metalloprotease is activated by thrombin and
attenuates ﬁbrinolysis (Redlitz et al. 1995). The
opposite would occur with the loss of Zn, resulting
in an increase in ﬁbrin degradation products such as
chain E, fragment double D. This fragment was shown
to increase by the end of the repletion period, which
may reﬂect a slow response to the changes in dietary
Zn.
Alternatively, the activation of glu- and lys-plas-
minogen via the intrinsic pathway involving Factor
XIIa was shown to be signiﬁcantly enhanced by Zn
(Schousboe 1997). The increase in chain E, fragment
double D following dietary repletion of Zn may,
therefore, be caused by an increase in the conversion
of plasminogen to plasmin, increasing ﬁbrolysis and
the ﬁbrin degradation products.
The levels of the unnamed protein, found among
the low- to medium-abundant proteins in the immu-
nodepleted plasma, did not signiﬁcantly change
between baseline and the end of the depletion period.
Its amino acid sequence includes many regions
associated with immunoglobulins (Entrez Protein:
Sequence Database). However, the levels of this
protein decreased signiﬁcantly by the end of the
repletion period when compared to the depletion
Fig. 3 Average normalized spot volumes for ﬁbrin b (acces-
sion #gi|223002), chain E fragment double D from ﬁbrin
(accession # gi|28373962), and unnamed protein (accession #
gi|34527413).Thebarsrepresentthemean ± SEM;n = 6.Bars
with different letters are signiﬁcantly different from each other,
p B 0.05
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123period. Its levels in the plasma were not signiﬁcantly
different from baseline, though.
Conclusions
Immunoafﬁnityprefractionationofplasmawasusedto
separate the plasma proteins into highly abundant and
medium/low abundant protein fractions. The separa-
tionofeach plasmaproteinfraction by2DEresultedin
theidentiﬁcationofthreeproteinsthatwereresponsive
to dietary Zn. Fibrin b and chain E fragment double D
from ﬁbrin are involved with blood clotting, and were
in the bound, highly abundant plasma protein fraction.
Fibrin b was the most responsive to changes in dietary
Zn, increasing during the depletion phase and decreas-
ing to baseline levels during the repletion phase.
Though sensitive to dietary zinc depletion, changes in
ﬁbrinbneedtobespeciﬁcforchangesinzincnutriture.
Zincisinvolvedinnumerousreactionsassociatedwith
inﬂammation and hemostasis. Zinc deﬁciency is pro-
inﬂammatory, and inﬂammation is linked to coagula-
tion and ﬁbrinolysis pathways, possibly through
stimulation of NFkB DNA binding, and inhibition of
PPARatransactivationactivity.Zincalsoenhancesthe
intrinsic pathway, and inhibits the extrinsic pathway,
of coagulation. Consequently, conditions that induce
inﬂammation or affect hemostasis may also affect
plasma ﬁbrin b levels apart from zinc status; future
research designed to test the hypothesis that plasma
ﬁbrin b levels are speciﬁc for assessing zinc nutriture
will be important in this regard.
Chain E fragment double D from ﬁbrin did not
change during Zn depletion and increased during the
repletion phase. An unnamed protein was identiﬁed in
the medium/low abundant protein fraction. This
protein has characteristics similar to immunoglobu-
lins, but is not associated with any of the immuno-
globulin classes. The levels of this unnamed protein
did not change signiﬁcantly during the Zn depletion
phase of the study, but signiﬁcantly decreased during
the repletion phase. Previous studies in this study
population have found that peripheral blood cell DNA
strand breaks also increase with Zn depletion and is
reversed with Zn repletion (Song et al. 2009).
Although DNA damage may be highly sensitive to
alterations in dietary zinc, its use as a speciﬁc Zn
dietary assessment method is limited since alterations
in DNA damage may also be affected by other
environmental stresses, including other micronutrient
deﬁciencies. Moreover, there is little standardization
for quantifying absolute levels of DNA damage using
single-cell electrophoresis as outlined in this previous
study. However, these results indicate that ﬁbrin b
may be another candidate for consideration as a blood
biomarker for assessing Zn status since it was
responsive to changes in dietary Zn. The ﬁndings of
thisstudyarelimitedbythesmallsamplesize(n = 6);
the Zn-dependent changes in plasma ﬁbrin b need to
be validated in more subjects in order to strengthen its
consideration as a Zn biomarker. Zn deﬁciency is an
important public health issue world-wide and there
exists a critical need to develop sensitive and speciﬁc
biomarkers for Zn deﬁciency in humans. The current
study highlights the use of an unbiased proteomic
approach to identify possible novel biomarkers for Zn
staus in humans.
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